D. E. Shaw & Co., Inc. Anavex Life Sciences Corp. Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 69,618 shares of AVXL stock, worth $286,826. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,618
Previous 53,454
30.24%
Holding current value
$286,826
Previous $497,000
28.77%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding AVXL
# of Institutions
159Shares Held
31.6MCall Options Held
910KPut Options Held
1.35M-
State Street Corp Boston, MA7.3MShares$30.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$27.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.41MShares$18.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.71MShares$7.06 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC851KShares$3.51 Million0.0% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $321M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...